
Pubmed-entry ::= {
  pmid 29696234,
  medent {
    em std {
      year 2018,
      month 4,
      day 27,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Reduce bladder cancer recurrence in patients treated for upper
 urinary tract urothelial carcinoma: The REBACARE-trial."
      },
      authors {
        names std {
          {
            name ml "van Doeveren T",
            affil str "Erasmus University Medical Center, Rotterdam, The
 Netherlands."
          },
          {
            name ml "van Leeuwen PJ",
            affil str "Erasmus University Medical Center, Rotterdam, The
 Netherlands."
          },
          {
            name ml "Aben KKH",
            affil str "Netherlands Comprehensive Cancer Organisation, The
 Netherlands.; Radboud University Medical Center, Nijmegen, The Netherlands."
          },
          {
            name ml "van der Aa M",
            affil str "Spaarne Medical Center, Hoofddorp, The Netherlands."
          },
          {
            name ml "Barendrecht M",
            affil str "Tergooi Medical Center, Hilversum, The Netherlands."
          },
          {
            name ml "Boeve ER",
            affil str "Fransiscus Medical Center, Rotterdam, The Netherlands."
          },
          {
            name ml "Cornel EB",
            affil str "Ziekenhuis Groep Twente, Almelo and Hengelo, The
 Netherlands."
          },
          {
            name ml "van der Heijden AG",
            affil str "Radboud University Medical Center, Nijmegen, The
 Netherlands."
          },
          {
            name ml "Hendricksen K",
            affil str "Netherlands Cancer Institute, Amsterdam, The
 Netherlands."
          },
          {
            name ml "Hirdes W",
            affil str "Isala Medical Center, Zwolle, The Netherlands."
          },
          {
            name ml "Kooistra A",
            affil str "Meander Medical Center, Amersfoort, The Netherlands."
          },
          {
            name ml "Kroon B",
            affil str "Rijnstate Medical Center, Arnhem, The Netherlands."
          },
          {
            name ml "Leliveld AM",
            affil str "University Medical Center Groningen, Groningen, The
 Netherlands."
          },
          {
            name ml "Meijer RP",
            affil str "University Medical Center Utrecht, Utrecht, The
 Netherlands."
          },
          {
            name ml "van Melick H",
            affil str "Sint Antonius Medical Center, Nieuwegein, The
 Netherlands."
          },
          {
            name ml "Merks B",
            affil str "Haaglanden Medical Center, Leidschendam, The
 Netherlands."
          },
          {
            name ml "de Reijke TM",
            affil str "Academic Medical Center, Amsterdam, The Netherlands."
          },
          {
            name ml "de Vries P",
            affil str "Zuyderland Medical Center, Heerlen, The Netherlands."
          },
          {
            name ml "Wymenga LFA",
            affil str "Martini Medical Center, Groningen, The Netherlands."
          },
          {
            name ml "Wijsman B",
            affil str "Elisabeth-TweeSteden Medical Center, Tilburg, The
 Netherlands."
          },
          {
            name ml "Boormans JL",
            affil str "Erasmus University Medical Center, Rotterdam, The
 Netherlands."
          }
        }
      },
      from journal {
        title {
          iso-jta "Contemp Clin Trials Commun",
          ml-jta "Contemp Clin Trials Commun",
          issn "2451-8654",
          name "Contemporary clinical trials communications"
        },
        imp {
          date std {
            year 2018,
            month 2,
            day 28
          },
          volume "9",
          pages "121-129",
          language "eng",
          pubstatus epublish,
          history {
            {
              pubstatus received,
              date std {
                year 2017,
                month 7,
                day 19
              }
            },
            {
              pubstatus revised,
              date std {
                year 2018,
                month 1,
                day 15
              }
            },
            {
              pubstatus accepted,
              date std {
                year 2018,
                month 1,
                day 19
              }
            },
            {
              pubstatus other,
              date std {
                year 2018,
                month 4,
                day 27,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus pubmed,
              date std {
                year 2018,
                month 4,
                day 27,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2018,
                month 4,
                day 27,
                hour 6,
                minute 1
              }
            }
          }
        }
      },
      ids {
        pubmed 29696234,
        doi "10.1016/j.conctc.2018.01.007",
        pii "S2451-8654(17)30134-5",
        other {
          db "pmc",
          tag str "PMC5898538"
        },
        other {
          db "ELocationID doi",
          tag str "10.1016/j.conctc.2018.01.007"
        }
      }
    },
    abstract "Background: Following radical nephro-ureterectomy for urothelial
 carcinoma of the upper urinary tract (UUT), the reported bladder recurrence
 rate of urothelial carcinoma is 22-47%. A single intravesical instillation of
 chemotherapy within 10 days following nephro-ureterectomy has the potential
 to decrease the risk of a bladder recurrence significantly. Despite
 recommendation by the European Association of Urology guideline to administer
 a single instillation postoperatively, the compliance rate is low because the
 risk of extravasation of chemotherapy. Aim: To reduce the risk of bladder
 cancer recurrence by a single intravesical instillation of Mitomycin
 immediately (within 3h) before radical nephro-ureterectomy or partial
 ureterectomy. Methods: Adult patients (age>/=18 years) with a (suspicion of
 a) urothelial carcinoma of the UUT undergoing radical nephro-ureterectomy or
 partial ureterectomy will be eligible and will receive a single intravesical
 instillation of Mitomycin within 3h before surgery. In total, 170 patients
 will be included in this prospective, observational study. Follow-up will be
 according to current guidelines. Results: The primary endpoint is the bladder
 cancer recurrence rate up to two years after surgery. Secondary endpoints
 are: a) the compliance rate; b) oncological outcome; c) possible
 side-effects; d) the quality of life; e) the calculation of costs of a single
 neoadjuvant instillation with Mitomycin and f) molecular characterization of
 UUT tumors and intravesical recurrences. Conclusions: A single intravesical
 instillation of Mitomycin before radical nephro-ureterectomy or partial
 ureterectomy may reduce the risk of a bladder recurrence in patients treated
 for UUT urothelial carcinoma and will circumvent the disadvantages of current
 therapy.",
    pmid 29696234,
    pub-type {
      "Journal Article"
    },
    status premedline
  }
}


